- Home
- GLRE vs RIGL Comparison
GLRE vs RIGL Comparison
Compare GLRE & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- RIGL
- Stock Information
- Founded
- GLRE 2004
- RIGL 1996
- Country
- GLRE Cayman Islands
- RIGL United States
- Employees
- GLRE N/A
- RIGL N/A
- Industry
- GLRE Property-Casualty Insurers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GLRE Finance
- RIGL Health Care
- Exchange
- GLRE Nasdaq
- RIGL Nasdaq
- Market Cap
- GLRE 492.2M
- RIGL 486.4M
- IPO Year
- GLRE 2007
- RIGL 2000
- Fundamental
- Price
- GLRE $13.24
- RIGL $20.09
- Analyst Decision
- GLRE
- RIGL Buy
- Analyst Count
- GLRE 0
- RIGL 5
- Target Price
- GLRE N/A
- RIGL $34.80
- AVG Volume (30 Days)
- GLRE 74.8K
- RIGL 223.6K
- Earning Date
- GLRE 03-04-2025
- RIGL 03-04-2025
- Dividend Yield
- GLRE N/A
- RIGL N/A
- EPS Growth
- GLRE N/A
- RIGL N/A
- EPS
- GLRE 2.53
- RIGL 0.22
- Revenue
- GLRE $702,254,000.00
- RIGL $157,374,000.00
- Revenue This Year
- GLRE N/A
- RIGL $51.34
- Revenue Next Year
- GLRE N/A
- RIGL $15.75
- P/E Ratio
- GLRE $5.23
- RIGL $91.32
- Revenue Growth
- GLRE 8.96
- RIGL 21.65
- 52 Week Low
- GLRE $11.72
- RIGL $7.48
- 52 Week High
- GLRE $15.82
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- GLRE 40.98
- RIGL 45.75
- Support Level
- GLRE $13.04
- RIGL $20.00
- Resistance Level
- GLRE $13.59
- RIGL $21.93
- Average True Range (ATR)
- GLRE 0.28
- RIGL 1.30
- MACD
- GLRE -0.01
- RIGL -0.27
- Stochastic Oscillator
- GLRE 21.88
- RIGL 2.01
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed, and income from investments.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.